Use of calcium channel antagonists in myocardial revascularization procedures.

[1]  F. Messerli.  Case-Control Study, Meta-analysis, and Bouillabaisse: Putting the Calcium Antagonist Scare into Context , 1995, Annals of Internal Medicine.

[2]  B. Psaty,et al.  Calcium Antagonists: Antagonists or Protagonists of Mortality in Elderly Hypertensives? , 1995, Journal of the American Geriatrics Society.

[3]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[4]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[5]  B. Troost,et al.  Surgical bleeding: unexpected effect of a calcium antagonist , 1995, BMJ.

[6]  M. Cohen,et al.  Treatment of postoperative hypertension after coronary artery bypass surgery. Double-blind comparison of intravenous isradipine and sodium nitroprusside. , 1994, Circulation.

[7]  R. Califf,et al.  A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. , 1994, The American journal of cardiology.

[8]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[9]  G. Schuler,et al.  Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. , 1994, British heart journal.

[10]  S. Yusuf,et al.  Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction , 1994, Coronary artery disease.

[11]  R. Califf,et al.  A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease , 1993 .

[12]  G. Schuler,et al.  Regular Physical Exercise and Low‐Fat Diet: Effects on Progression of Coronary Artery Disease , 1992, Circulation.

[13]  R. Califf.  Why are large-scale trials needed? , 1992 .

[14]  E. Antman,et al.  Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. , 1991, Circulation.

[15]  M. Fishbein,et al.  A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. , 1991, Journal of the American College of Cardiology.

[16]  J. O’Keefe,et al.  Effects of diltiazem on complications and restenosis after coronary angioplasty. , 1991, The American journal of cardiology.

[17]  J. Spatt,et al.  Nifedipine reduces the incidence of myocardial infarction and transient ischemia in patients undergoing coronary bypass grafting. , 1991, Circulation.

[18]  W. Vetter,et al.  Ca2+-channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Meier,et al.  Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. , 1986, Journal of the American College of Cardiology.

[20]  M. Bourassa,et al.  Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. , 1985, American heart journal.

[21]  W. Parmley,et al.  Modification of experimental atherosclerosis by calcium-channel blockers. , 1985, The American journal of cardiology.

[22]  Y. Ikeda,et al.  Inhibition of Human Platelet Functions by Verapamil , 1981, Thrombosis and Haemostasis.

[23]  S. Oparil,et al.  Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. , 1980, The American journal of cardiology.

[24]  D. Kramsch,et al.  Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis. , 1980, The Journal of clinical investigation.

[25]  J. Laragh,et al.  Systemic hypertension associated with coronary artery bypass surgery. Predisposing factors, hemodynamic characteristics, humoral profile, and treatment. , 1977, The Journal of thoracic and cardiovascular surgery.